Investors
Opyl is headquartered in Melbourne, Australia and listed on the Australian Stock Exchange (ASX:OPL)
ASX Announcements
Opyl Appoints Global Clinical Trials And Health Tech Expert, Dr. Hugo Stephenson, As Board Advisor
downloadSuccessful Placement of Shortfall Shares From Rights Issue
downloadOpyl Rights Issue Results
downloadResignation of Director – Dr Julian Chick
downloadNotice of initial substantial holder – 13 Feb 2023
downloadOpyl enters into MSA and new clinical trial recruitment
downloadQuarterly Reports
Opyl Appendix 4C – Quarter 3 (Q3) ending 31 March 2023
downloadOpyl Appendix 4D – Half-year ending 31 December 2022
downloadOpyl Appendix 4C – Quarter 2 (Q2) ending 31 December 2022
downloadOpyl Appendix 4C – Quarter (Q1) ending 30 September 2022
downloadOpyl Appendix 4C – Quarter (Q4) ending 30 June 2022
downloadOpyl Appendix 4C – Quarter (Q3) ending 31 March 2022
downloadCorporate Governance
Opyl – Corporate Governance Statement 2022
downloadOpyl – Constitution 2022
downloadOpyl – Audit and Risk Committee Charter 2020
downloadOpyl – Board Charter 2020
downloadOpyl – Code of Conduct 2020
downloadOpyl – Diversity Policy 2020
downloadOpyl – Remuneration and Nomination Committee Charter 2020
downloadOpyl – Trading Policy 2020
downloadOpyl – Whistleblower 2020
downloadOpyl – Disclosure and Communication Policy 2020
downloadOpyl – Appendix 4G
downloadBoard and Management Team
Mark Ziirsen
Chairman
Michelle Gallaher
Chief Executive Officer
Damon Rasheed
Executive Director
Dr Megan Robertson
Non Executive Director
David Iilja
Company Secretary